# US 2016/0256524 A1 · Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256524 A1
- Document ID: US20160256524A1
- Status: Published application
- Kind: A1
- Application number: 15/071,108
- Filed: 2016-03-15
- Published: 2016-09-08
- Earliest claimed: 2008-03-13
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Stephen M. STRITTMATTER
- Web page: https://patentgrep.com/patent/US20160256524A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 47/56: the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K 51/0406: {Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines}
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/12: catalytic nucleic acids, e.g. ribozymes
- C12N 2310/122: Hairpin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.

## Claims

### Claim 1

A method of treating chronic spinal cord injury in a mammal in need thereof, comprising administering to the mammal by bolus injection a therapeutically effective amount of a Nogo-receptor antagonist.

### Claim 2

A method for stimulating axonal growth following chronic spinal cord injury, comprising administering by bolus injection a therapeutically effective amount of a Nogo-receptor antagonist.

### Claim 3 (depends on 1)

The method of claim 1, wherein said Nogo-receptor antagonist stimulates axonal growth.

### Claim 4 (depends on 1)

The method of claim 1, wherein said chronic spinal cord injury is a spinal contusion.

### Claim 5 (depends on 1)

The method of claim 1, wherein said Nogo-receptor antagonist is administered directly into the central nervous system, intracerebroventricularly, or intrathecally.

### Claim 6 (depends on 1)

The method of claim 1, wherein said Nogo-receptor antagonist is administered parenterally or intraventricularly.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from 0.001 mg/kg to 10 mg/kg of Nogo-receptor antagonist.

### Claim 8 (depends on 1)

The method of claim 1, wherein said Nogo-receptor antagonist is a Nogo receptor-1 polypeptide.

### Claim 9 (depends on 8)

The method of claim 8, wherein said Nogo receptor-1 polypeptide is a soluble Nogo receptor-1 polypeptide.

### Claim 10 (depends on 9)

The method of claim 9, wherein said soluble Nogo receptor-1 polypeptide is 90% identical to a reference amino acid sequence selected from the group consisting of:
(a) amino acids 26 to 310 of SEQ ID NO:10 or 11;
(b) amino acids 26 to 344 of SEQ ID NO:10 or 11;
(c) amino acids 26 to 445 of SEQ ID NO:10 or 11;
(d) amino acids 26 to 309 of SEQ ID NO:10 or 11;
(e) amino acids 27 to 310 of SEQ ID NO:10 or 11;
(f) amino acids 28 to 344 of SEQ ID NO:10 or 11;
(g) amino acids 29 to 445 of SEQ ID NO:10 or 11;
(h) amino acids 30 to 309 of SEQ ID NO:10 or 11;
(i) amino acids 1 to 310 of SEQ ID NO:10 or 11;
(j) amino acids 1 to 344 of SEQ ID NO:10 or 11;
(k) amino acids 1 to 445 of SEQ ID NO:10 or 11;
(l) amino acids 1 to 309 of SEQ ID NO:10 or 11; and
(m) a combination of one or more of said reference amino acid sequences.

### Claim 11 (depends on 10)

The method of claim 10, wherein said soluble Nogo receptor-1 polypeptide is selected from the group consisting of:
(a) amino acids 26 to 310 of SEQ ID NO:10 or 11;
(b) amino acids 26 to 344 of SEQ ID NO:10 or 11;
(c) amino acids 26 to 445 of SEQ ID NO:10 or 11;
(d) amino acids 26 to 309 of SEQ ID NO:10 or 11;
(e) amino acids 27 to 310 of SEQ ID NO:10 or 11;
(f) amino acids 27 to 344 of SEQ ID NO:10 or 11;
(g) amino acids 27 to 445 of SEQ ID NO:10 or 11;
(h) amino acids 27 to 309 of SEQ ID NO:10 or 11;
(i) amino acids 1 to 310 of SEQ ID NO:10 or 11;
(j) amino acids 1 to 344 of SEQ ID NO:10 or 11;
(k) amino acids 1 to 445 of SEQ ID NO:10 or 11;
(l) amino acids 1 to 309 of SEQ ID NO:10 or 11; and
(m) a combination of one or more of said reference amino acid sequences.

### Claim 12 (depends on 8)

The method of claim 8, wherein said Nogo receptor-1 polypeptide further comprises a non-NgR1 moiety.

### Claim 13 (depends on 12)

The method of claim 12, wherein said non-NgR1 moiety is a heterologous polypeptide fused to said Nogo receptor-1 polypeptide.

### Claim 14 (depends on 13)

The method of claim 13, wherein said heterologous polypeptide is selected from the group consisting of:
(a) serum albumin;
(b) an Fc region;
(c) a signal peptide;
(d) a polypeptide tag; and
(e) a combination of two or more of said heterologous polypeptides.

### Claim 15 (depends on 12)

The method of claim 12, wherein said non-NgR1 moiety is a polymer conjugated to said Nogo receptor-1 polypeptide.

### Claim 16 (depends on 8)

The method of claim 8, wherein said Nogo receptor-1 polypeptide is a cyclic polypeptide.

### Claim 17 (depends on 1)

The method of claim 1, wherein said Nogo receptor antagonist comprises an antibody or antigen-binding fragment thereof that binds to a mammalian Nogo-receptor.

### Claim 18 (depends on 1)

The method of claim 1, wherein said Nogo-receptor antagonist is an isolated polynucleotide selected from the group consisting of:
(a) an antisense polynucleotide;
(b) a ribozyme;
(c) a small interfering RNA (siRNA); and
(d) a small-hairpin RNA (shRNA).

### Claim 19 (depends on 10)

The method of claim 10, wherein said Nogo receptor-1 polypeptide comprises a substitution of an amino acid with a different amino acid and wherein said substitution is at a position selected from the group consisting of: C266 of said reference amino acid sequence; C309 of said reference amino acid sequence; and C335 of said reference amino acid sequence.
